Loading…
Beijing Xinggu Lvsan Technology Co., Ltd., a pharmaceutical drug manufacturer, received an FDA warning letter in October 2022 regarding Current Good Manufacturing Practice (CGMP) violations and issues with finished pharmaceutical products. Based on the subject line, the company appears to have violations related to adulterated drugs, unapproved new drug products, and misbranding. The warning was issued by the FDA's Center for Drug Evaluation and Research (CDER), indicating the agency's concern with the company's manufacturing practices and product compliance. Please note this summary is based on limited metadata; the full warning letter text would provide specific details regarding the violations cited.